Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4T916)

Drug Name

BI-836845 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Insulin-like growth factor-I (IGF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Xentuzumab	DM4ZIDH	Breast cancer	2C60-2C65	Phase 2	[3]
MEDI-573	DMNL8MO	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Insulin-like growth factor-I (IGF1)	TTT6LOU	IGF1_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02145741) Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours. U.S. National Institutes of Health.
2	Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin.Mol Cancer Ther.2014 Feb;13(2):399-409.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.